Conference Coverage

Statins may do double duty as antidepressants


 

REPORTING FROM ECNP 2019

Femke Lamers, PhD, presented evidence based on the nearly 3,000-subject longitudinal Netherlands Study of Depression and Anxiety that roughly one-quarter of individuals with major depressive disorder have a distinct subtype of nonmelancholic depression characterized by a clustering of obesity, inflammation, increased appetite, fatigue, hypersomnia, and increased levels of insulin and leptin. She calls it immunometabolic depression. She and her coinvestigators in the international Psychiatric Genomics Consortium have demonstrated that this phenotypic clustering is associated with a shared genetic vulnerability between major depression and obesity (JAMA Psychiatry. 2017 Dec 1;74[12]:1214-25).

Dr. Femke Lamers, an epidemiologist at the University of Amsterdam Bruce Jancin/MDedge News

Dr. Femke Lamers

“Major depressive disorder is not a one-size-fits-all disorder. There is an immunometabolic form of depression,” declared Dr. Lamers, an epidemiologist at the University of Amsterdam.

All speakers reported having no financial conflicts of interest.

Pages

Recommended Reading

Depressive symptoms are associated with stroke risk
Journal of Clinical Outcomes Management
Unipolar vs bipolar depression: A clinician’s perspective
Journal of Clinical Outcomes Management
Hazardous cannabis use in MS linked to anxiety, depression
Journal of Clinical Outcomes Management
Ask patients about worst example of suicidal ideation
Journal of Clinical Outcomes Management
Suicide rates rise in U.S. adolescents and young adults
Journal of Clinical Outcomes Management
Anticholinergic drugs linked to dementia in older populations
Journal of Clinical Outcomes Management
Nothing to sneeze at: Upper respiratory infections and mood disorders
Journal of Clinical Outcomes Management
Mindfulness-based relapse prevention tied to lower anxiety, depression
Journal of Clinical Outcomes Management
Antidepressants for pediatric patients
Journal of Clinical Outcomes Management
Oral drug for postpartum depression aces phase 3 trial
Journal of Clinical Outcomes Management